Repeated botulinum toxin injections can improve mobility in patients with spinal cord lesions

Europa Medicophysica

Volumn 43, Issue 3, 2007, Pages 319-325

  Catz, A ^a,b   Barkol, H ^a,b   Steinberg, F ^a   Ronen, J ^a,b   Bluvshtein, V ^a,b   Keren, O ^a,b  

^a LOEWENSTEIN REHABILITATION HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Botulinum toxins; Muscle spasticity; Neuromuscolar block; Spinal cord compression

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADULT; AGED; ARTICLE; CERVICAL SPINE; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SPASTICITY; SPINAL CORD DISEASE; TREATMENT OUTCOME; VERTEBRA; WALKING;

ADULT; AGED; BOTULINUM TOXIN TYPE A; CERVICAL VERTEBRAE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; RANGE OF MOTION, ARTICULAR; SPINAL CORD DISEASES; THORACIC VERTEBRAE; TREATMENT OUTCOME; WALKING;

EID: 36049020929     PISSN: 00142573     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Gans BM, Glenn MB. Introduction, In: Glenn MB, Whyte J, editors. The practical management of spasticity in children and adults. Philadelphia: Lea & Febiger; 1990. p. 1-7.
2. Pandyan AD, Gregoric M, Barnes MP, Wood D, Van Wijck F, Burridge J et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil 2005;27:2-6.
3. Satkunam LE, Rehabilitation medicine: 3. Management of adult spasticity. Can Med Assoc J 2003;169:1173-9.
4. Matthews PBC, Rushworth G. The relative sensitivity of muscle nerve fibres to procaine. J Physiol 1957;135:263-9.
5. Wood KE. The use of phenol as a neurolytic agent: A review. Pain 1978;5:205-29.
6. Tsui JK, Fross RP, Calne S, Calne DB. Local treatment of spasmodic torticollis with botulinum toxin. Can I Neurol Sci 1987;14: 533-5.
7. Gracies JM. Physiological effects of botulinum toxin in spasticity. Mov Disord 2004;19 Suppl 8:120-8.
8. Giladi N, Meer J, Kidan C, Greenberg E, Gross B, Honigman S. Interventional neurology: botulinum toxin as a potent symptomatic treatment in neurology. Israel J Med Sci 1994;30:1-10.
9. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-5.
10. Grazko MA, Polo B, Jabbari B. Botulinum Toxin A for spasticity, muscle spasms and rigidity. Neurology 1995;45:712-7.
11. Al-Khodairy AT, Gobelet C, Rossier AB. Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients? Spinal Cord 1998;36:854-8.
12. Comella CL, Pullman SL. Botulinum toxin in neurological disease. Muscle Nerve 2004;29:628-44.
13. Pfister AA, Roberts AG, Taylor HM, Noel-Spaudling S, Damian MM, Charles PD. Spasticity in adults living in a developmental center. Arch Phys Med Rehabil 2003;84:1808-12.
14. Hesse S, Werner C. Poststroke motor dysfunction and spasticity: novel pharmacological and physical treatment strategies. CNS Drugs 2003;17:1093-107.
15. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-7.
16. Dressier D. Clinical features of antibody-induced complete secondary failure of botulinum toxin therapy. Eur Neurol 2002;48: 26-9.
17. Giladi N, Ohri A, Catz A. The effect of Botulinum Toxin on leg spasticity in patients with spinal cord lesions. Tel-Aviv: Ministry of Defence; 1996.
18. Keren O, Steinberg F, Catz A, Giladi N. Botulinum Toxin injection into the motor end plate for spasticity in patients with spinal cord lesions. Harefua 2000;138:204-8.
19. Siatkowski RM, Tyutyunikov A, Biglan AW, Scalise D, Genovese C, Raikow RB et al. Serum antibody production to botulinum A toxin. Ophthalmology 1993;100:1861-6.
20. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-6.
21. Bohnnonn RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-7.
22. Catz A, Itzcovich M, Agranov E, Tamir A. SCIM - Spinal Cord Independence Measure: a new disability scale for patients with spinal cord lesions. Spinal Cord 1997;35:850-6.
23. Itzkovich M, Tripolski M, Zeilig G, Ring H, Rosentul N, Ronen J et al. Rasch analysis of the Catz-Itzkovich Spinal Cord Independence Measure. Spinal Cord 2002;40:396-407.
24. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry 2004;75:951-7.